While we've been curating 3Q23 Results reports, we've had eyes on drug approvals, Business Development activities, & even some patent ...

We found ourselves looking closer at the disease, the history of weight loss medications, and the potential impact of effective weight manag

This week we had Eyes On the upcoming IRA Drug pricing negotiations - here's some of the news and views we saw.

We have Eyes on Pharma Conferences this week. Don't forget to check PharmaTell Studio for the latests Planners, Insights, and Key Takes.

The MedTech sector seemed to take the brunt of the 2022 market decline but looking to forward there may be light at the end of the tunnel.

We’ve had Eyes On – Some of the Post Holiday /Pre-Earnings News Snippets As the companies and the markets gear up for Results, tucked in...